Pulsenmore Ltd. Ordinary Shares(PLSM)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$346.12
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for PLSM

11/13/2026: PLSM (1-star) is currently NOT-A-BUY. Pass it for now.

Pulsenmore Ltd. is an emerging medical device company specializing in smartphone-docked, portable ultrasound systems for home-use remote diagnostics. The company's main strengths lie in its innovative, cost-effective hardware design and recent regulatory milestones, including U.S. FDA clearance. Its primary growth opportunity centers on expanding commercial penetration within the U.S. telehealth and virtual prenatal monitoring markets. Key risks involve intense competition from well-funded ultrasound incumbents, execution uncertainties in scaling distribution, and ongoing net losses. The stock suits high-risk growth investors willing to monitor clinical adoption milestones and cash burn trends closely.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fit while signal remains positiveThe company offers exposure to rapid expansion in telehealth and home-use diagnostic medical devices.
Momentum investorMixed fitMomentum fit remains conditional on sustained breakout volume and positive near-term commercial news flow.
Value investorWeak fitThe stock trades at an early commercial stage with ongoing net losses and unproven long-term earnings stability.
Dividend investorWeak fitPulsenmore does not pay dividends and reinvests all capital into growth.
Low-risk investorWeak fitHigh share price volatility and micro-cap liquidity risks make it unsuitable for conservative investors.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighLow public float and micro-cap status result in sharp intraday and multi-week price swings.
Valuation riskMedium / highValuation relies heavily on future market adoption assumptions rather than historical cash generation.
Competition risk (portable ultrasound and telehealth)HighWell-capitalized medical device giants and handheld ultrasound pioneers pose fierce competitive threats.
Business qualityMediumProprietary telehealth technology is robust, but commercial scale and profitability are still unproven.
Dividend incomeLow / noneNo distributions are paid to shareholders.
Execution riskHighSuccessful scaling depends on physician adoption and navigating complex foreign reimbursement frameworks.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 8.97M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) 22.8K shares
Beta 0.44
52 Weeks Range 1.38 - 2226.00
Updated Date 11/14/2026
52 Weeks Range 1.38 - 2226.00
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) -1.33

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Devices

BUY participation
62.5%
Active BUY / eligible
5 / 8
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit 0%
Avg. Invested days 0
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
PLSM receives a 3-star rating, supported by solid company fundamentals. The rating is constrained by weak unit economics, and soft analyst coverage.

Company Fundamentals

★★★★★
PLSM has solid overall fundamentals (4 stars), with moderate financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+56.7%) and strong revenue growth (+315.2%) are partially offset by weak cash generation (FCF margin -82.5%), weak profitability (net margin -39.6%).

Financial Health Rating

★★★★★
PLSM's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 69.8%). Cash strength is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is PLSM's strongest growth driver at +315.2% FY2025 versus FY2024 (strong, 5 stars). By comparison, earnings growth (+56.7%, strong) is also strong, while free-cash-flow growth (+3.5%, moderate) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 4.4% and approximately 52.7% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 35.78% supports management-shareholder alignment.

Unit Economics (Per $1K Revenue)

★★★★★
PLSM generates approximately $842 of gross profit, $-304 of operating income, and $-825 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -0.01% (Tax Credit)

Quantitative Style Profile

★★★★★
PLSM has a liquid, relatively low-volatility profile. No single quantitative factor dominates as a drawback.

Style Classification

Quality Focused

Value-OrientedLow VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Home Ultrasound Systems & HardwareDirect sales and distribution of Pulsenmore ES and FC docking hardware units to healthcare providers and clinics.The company generates core revenue by selling specialized portable ultrasound hardware docking devices.
Telehealth Software & ServicesAssociated recurring software access fees, clinician dashboard subscriptions, and remote monitoring service packages.Recurring income is tied to software platform utilization and remote patient management tools.
Geographic ExposureCommercial operations spanning Israel, Europe, and initial market entries across the United States.International expansion into the U.S. market is the primary driver for future geographic diversification.

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value -11.61M
Price to Sales(TTM) 0.7
Enterprise Value -11.61M
Price to Sales(TTM) 0.7
Enterprise Value to Revenue 0.07
Enterprise Value to EBITDA -
Shares Outstanding 6.50M
Shares Floating 3.42M
Shares Outstanding 6.50M
Shares Floating 3.42M
Percent Insiders 35.78
Percent Institutions 4.42

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.